Frazier Life Sciences Management’s Jade Biosciences JBIO Stock Holding History

Frazier Life Sciences Management’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,413,280	Closed	-$12.2M	–	44
2025 Q3	$12.2M	Sell	1,413,280 -358,836	-20%	-$2.93M	0.37%	37
2025 Q2	$17.7M	Buy	+1,772,116	New	+$60.3M	0.71%	31
2024 Q2	–	Sell	-34,425	Closed	-$35.6M	–	51
2024 Q1	$35.6M	Hold	34,425	–	–	1.5%	21
2023 Q4	$27.3M	Hold	34,425	–	–	1.46%	20
2023 Q3	$16.4M	Buy	34,425 +6,000	+21%	+$3.25M	1.09%	21
2023 Q2	$17.1M	Buy	28,425 +18,765	+194%	+$12M	1.02%	25
2023 Q1	$6.82M	Buy	+9,660	New	+$8.01M	0.49%	38

Other funds holding JBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

Frazier Life Sciences Management's JBIO Position: Q4 2025 in Review

Frazier Life Sciences Management sold out of Jade Biosciences (JBIO) in Q4 2025, closing a stake of 1,413,280 shares — an estimated $12.2M sold.

Frazier Life Sciences Management first reported a position in JBIO in Q1 2023 and held it in 7 quarters. The position peaked at $35.6M in Q1 2024. 105 funds tracked by Wall St. Rank hold JBIO as of Q4 2025.

Frazier Life Sciences Management reported no remaining Jade Biosciences position as of Q4 2025 after selling out during the quarter.
Frazier Life Sciences Management sold 1,413,280 Jade Biosciences shares in Q4 2025, an estimated $12.2M.
Frazier Life Sciences Management first reported a position in Jade Biosciences in Q1 2023 and held it in 7 quarters.
Frazier Life Sciences Management's Jade Biosciences position peaked at $35.6M in Q1 2024.
105 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2025.

Based on Frazier Life Sciences Management's 13F filing for Q4 2025, filed 13 Feb 2026.